

Freedom of Information Request: Our Reference CTMUHB_439_23

You asked:

I am researching the usage of high-cost drugs in ophthalmology. Your answer to the following question will be highly appreciated.

For the 4 months from May to August 2023, how many patients received the following intra-vitreal treatments for any eye condition:

- Aflibercept
- Bevacizumab
- Brolucizumab
- Dexamethasone
- Faricimab
- Ranibizumab – Lucentis
- Ranibizumab – Ongavia

Our response:

Under section 21 of the Act, Cwm Taf Morgannwg University Health Board is not required to provide information in response to a request if it is already reasonably accessible to you. We have answered a previous request in relation to the information you require, and this response is published via our [Disclosure Log](#) on the [Cwm Taf University Morgannwg Health Board](#) web site.

For ease of access, we have attached a link directly to the information below:

- [CTMUHB 405 23](#)